Vimian’s Interim Report for the first quarter of 2024

Regulatory press release
May 02 2024

Vimian’s Interim Report for the first quarter of 2024

Normalising sales pattern in MedTech

  • Net revenue increased by 4 per cent to EUR 91.3m (88.1) with organic growth of 1 per cent
  • Adjusted EBITA EUR 24.1m (26.1) corresponding to a margin of 26.3 per cent (29.6)
  • Operating profit (EBIT) of EUR 13.4m (18.5)
  • Profit of EUR 3.7m (5.5) and earnings per share before and after dilution EUR 0.01 (0.01)
  • Cash flow from operating activities of EUR 11.2m (1.1)

“The animal health market continues to show solid growth in the first quarter. Vimian’s organic growth of 1 per cent and adjusted EBITA margin of 26.3 (29.6) per cent reflects our decision to reduce the size of the annual ordering program in US MedTech, to better phase sales across the year with no impact on the full year. Specialty Pharma and Veterinary Services continue to deliver strong organic growth of 11 and 15 per cent respectively”, says Patrik Eriksson, CEO of Vimian Group and continues:

“During the first quarter, we completed a successful rights issue, announced new financial targets and our intention to change listing venue to Nasdaq Stockholm main market. With these building blocks in place, we are well equipped to create significant shareholder value over the years to come.“

A telephone and webcast will be held for investors, analysts, and media, today at 09.00 (CET). The conference will be held in English and include a question-and-answer session.

To attend the telephone conference:
Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.

To attend the webcast:

Related presentation materials will be available on Vimian’s website ( ahead of the telephone and web conference.